ClinicalTrials.gg
CompletedNCT04638829Updated Jan 16, 2025Results posted

Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim

A Phase 4 interventional study of Avatrombopag Oral Tablet in Immune Thrombocytopenia, sponsored by Sobi, Inc.. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-16.

Sponsored by Sobi, Inc. · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 5 under way, 2 of them phase 3. avatrombopag · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
6th of 16
60 · median 53
Started
2021
with 3 others
Phase 4
2 of 16
1 open now
Registered
9th of 16
by date
Lead sponsor
4 of 16
Sobi, Inc.

Among the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 6th largest by enrollment, is one of 4 that started in 2021, is one of 2 in phase 4, and was the 9th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About avatrombopag

avatrombopag: first FDA approval 2018 (DOPTELET), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

Evaluate the safety and tolerability of avatrombopag given for 90 days after stopping treatment with eltrombopag or romiplostim.

Read the detailed description

This Phase 4, prospective, multi-center, open-label study will evaluate safety, platelet count, and subject reported medication satisfaction in adult subjects with chronic ITP after switching to avatrombopag from eltrombopag or romiplostim. At least 100 subjects will be enrolled, 50 (±10) who have received eltrombopag and 50 (±10) who have received romiplostim for at least 90 days prior to study entry.

03

Conditions studied

  • Immune Thrombocytopenia

Keywords

  • ITP
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has been undergoing treatment for primary ITP with eltrombopag or romiplostim for at least 90 days prior to the Screening Visit/Visit 1.
  • Subject has had a previous response (at any time) to either eltrombopag or romiplostim, defined as at least 2 counts ≥50×10⁹/L. Subject is willing and able to comply with all aspects of the protocol, including completing the self-administered Treatment Satisfaction Medication Questionnaire (TSQM).

Exclusion criteria

Exclusion Criteria:

  • Subject is currently receiving chemotherapy or radiation for any form of cancer.
  • Subject with conditions that are likely to prevent them from accurately and reliably completing study assessments, including evidence of moderate to severe dementia, and/or severe and progressive medical illness, as determined by the Investigator.
  • Any previous avatrombopag use.
  • Previous participation in this study; a subject may not re-enroll after prior discontinuation or completion.
  • Enrollment in another clinical study with any drug or device within 30 days of Baseline (or 5 half-lives, whichever is longer); however, participation in observational studies within the previous 30 days is permitted.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Other
    Avatrombopag

    Avatrombopag 20 mg oral tablet formulation for 90 days

    Drug: Avatrombopag Oral Tablet

Interventions

  • Avatrombopag 20 mg given daily for 90 days. Initial dose and dose adjustments will be determined by the physician along with the Doptelet prescribing information

    Also known as: Doptelet

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability (Adverse Events)

    Safety and Tolerability of Avatrombopag given for 90 days after stopping eltrombopag or romiplostim The incidence and severity of adverse events (AEs), serious adverse events (SAE) and adverse events of special interest (AESIs) will be summarized for all enrolled subjects using counts and percentages. Treatment-emergent AEs and SAEs will be summarized overall, by system organ class, and by preferred term. AESIs will be summarized by event type (thromboembolic events and bleeding events). In addition, treatment-emergent AEs will be summarized by severity and by relationship to study drug. Bleeding events reported during the study will be summarized by WHO grade.

    Time frame: Screening through Day 90 or End of Study

Secondary outcomes

  1. Change From Baseline TSQM Convenience Domain Score

    Evaluate the change in subject reported outcomes (TSQM - Treatment Satisfaction Questionnaire for Medication) from Baseline. Convenience domain score ranges from 0 to 100, and a higher score indicates a better outcome. Mean Difference was computed as Day 90 minus Baseline and, therefore, a positive mean difference indicates an increase in the score from Baseline to Day 90.

    Time frame: Day 90

  2. Change From Baseline TSQM Side Effects Domain Score

    Evaluate the change in subject reported outcomes (TSQM - Treatment Satisfaction Questionnaire for Medication) from Baseline. Side Effects domain score ranges from 0 to 100, and a higher score indicates a better outcome. Mean Difference was computed as Day 90 minus Baseline and, therefore, a positive mean difference indicates an increase in the score from Baseline to Day 90.

    Time frame: Day 90

  3. Change From Baseline TSQM Effectiveness Domain Score

    Evaluate the change in subject reported outcomes (TSQM - Treatment Satisfaction Questionnaire for Medication) from Baseline. Effectiveness domain score ranges from 0 to 100, and a higher score indicates a better outcome. Mean Difference was computed as Day 90 minus Baseline and, therefore, a positive mean difference indicates an increase in the score from Baseline to Day 90.

    Time frame: Day 90

  4. Change From Baseline TSQM Global Satisfaction Domain Score

    Evaluate the change in subject reported outcomes (TSQM - Treatment Satisfaction Questionnaire for Medication) from Baseline. Global Satisfaction domain score ranges from 0 to 100, and a higher score indicates a better outcome. Mean Difference was computed as Day 90 minus Baseline and, therefore, a positive mean difference indicates an increase in the score from Baseline to Day 90.

    Time frame: Day 90

  5. Proportion of Subjects Who Have a Platelet Count Between ≥50×10^9/L to ≤200×10^9/L

    Time frame: Day 15

  6. Proportion of Subjects Who Have a Platelet Count Between ≥50×10^9/L to ≤200×10^9/L

    Time frame: Day 30

  7. Proportion of Subjects Who Have a Platelet Count Between ≥50×10^9/L to ≤200×10^9/L

    Time frame: Day 60

  8. Proportion of Subjects Who Have a Platelet Count Between ≥50×10^9/L to ≤200×10^9/L

    Time frame: Day 90

07

Results

Posted Jan 16, 2025

Participant flow

Participant flow — Overall Study
MilestoneAvatrombopag
Started60
Completed57
Not completed3

Outcome measures

PrimarySafety and Tolerability (Adverse Events)

Safety and Tolerability of Avatrombopag given for 90 days after stopping eltrombopag or romiplostim The incidence and severity of adverse events (AEs), serious adverse events (SAE) and adverse events of special interest (AESIs) will be summarized for all enrolled subjects using counts and percentages. Treatment-emergent AEs and SAEs will be summarized overall, by system organ class, and by preferred term. AESIs will be summarized by event type (thromboembolic events and bleeding events). In addition, treatment-emergent AEs will be summarized by severity and by relationship to study drug. Bleeding events reported during the study will be summarized by WHO grade.

Time frame:
Screening through Day 90 or End of Study
Reported as:
Count of participants · Participants
Safety and Tolerability (Adverse Events)
ParticipantsAvatrombopag
TEAEs35
SAEs6
AESIs1
Related TEAEs15
Severe TEAEs8
TEAEs leading to study drug discontinuation2
SecondaryChange From Baseline TSQM Convenience Domain Score

Evaluate the change in subject reported outcomes (TSQM - Treatment Satisfaction Questionnaire for Medication) from Baseline. Convenience domain score ranges from 0 to 100, and a higher score indicates a better outcome. Mean Difference was computed as Day 90 minus Baseline and, therefore, a positive mean difference indicates an increase in the score from Baseline to Day 90.

Time frame:
Day 90
Reported as:
Mean · Mean difference in convenience score
Change From Baseline TSQM Convenience Domain Score
Mean difference in convenience scoreAvatrombopag
Change From Baseline TSQM Convenience Domain Score13.5 (6.9 to 20.1)
Statistical analysis
  • Avatrombopag · t-test, 2 sided · p = 0.0001
SecondaryChange From Baseline TSQM Side Effects Domain Score

Evaluate the change in subject reported outcomes (TSQM - Treatment Satisfaction Questionnaire for Medication) from Baseline. Side Effects domain score ranges from 0 to 100, and a higher score indicates a better outcome. Mean Difference was computed as Day 90 minus Baseline and, therefore, a positive mean difference indicates an increase in the score from Baseline to Day 90.

Time frame:
Day 90
Reported as:
Mean · Mean difference in side effects score
Change From Baseline TSQM Side Effects Domain Score
Mean difference in side effects scoreAvatrombopag
Change From Baseline TSQM Side Effects Domain Score8.3 (2.1 to 14.4)
Statistical analysis
  • Avatrombopag · t-test, 2 sided · p = 0.0093
SecondaryChange From Baseline TSQM Effectiveness Domain Score

Evaluate the change in subject reported outcomes (TSQM - Treatment Satisfaction Questionnaire for Medication) from Baseline. Effectiveness domain score ranges from 0 to 100, and a higher score indicates a better outcome. Mean Difference was computed as Day 90 minus Baseline and, therefore, a positive mean difference indicates an increase in the score from Baseline to Day 90.

Time frame:
Day 90
Reported as:
Mean · Mean difference in effectiveness score
Change From Baseline TSQM Effectiveness Domain Score
Mean difference in effectiveness scoreAvatrombopag
Change From Baseline TSQM Effectiveness Domain Score14.4 (7.0 to 21.8)
Statistical analysis
  • Avatrombopag · t-test, 2 sided · p = 0.0003
SecondaryChange From Baseline TSQM Global Satisfaction Domain Score

Evaluate the change in subject reported outcomes (TSQM - Treatment Satisfaction Questionnaire for Medication) from Baseline. Global Satisfaction domain score ranges from 0 to 100, and a higher score indicates a better outcome. Mean Difference was computed as Day 90 minus Baseline and, therefore, a positive mean difference indicates an increase in the score from Baseline to Day 90.

Time frame:
Day 90
Reported as:
Mean · Mean difference in global satisfaction
Change From Baseline TSQM Global Satisfaction Domain Score
Mean difference in global satisfactionAvatrombopag
Change From Baseline TSQM Global Satisfaction Domain Score14.2 (8.8 to 19.5)
Statistical analysis
  • Avatrombopag · t-test, 2 sided · p = <0.0001
SecondaryProportion of Subjects Who Have a Platelet Count Between ≥50×10^9/L to ≤200×10^9/L
Time frame:
Day 15
Reported as:
Count of participants · Participants
Proportion of Subjects Who Have a Platelet Count Between ≥50×10^9/L to ≤200×10^9/L
ParticipantsAvatrombopag
Proportion of Subjects Who Have a Platelet Count Between ≥50×10^9/L to ≤200×10^9/L19
SecondaryProportion of Subjects Who Have a Platelet Count Between ≥50×10^9/L to ≤200×10^9/L
Time frame:
Day 30
Reported as:
Count of participants · Participants
Proportion of Subjects Who Have a Platelet Count Between ≥50×10^9/L to ≤200×10^9/L
ParticipantsAvatrombopag
Proportion of Subjects Who Have a Platelet Count Between ≥50×10^9/L to ≤200×10^9/L33
SecondaryProportion of Subjects Who Have a Platelet Count Between ≥50×10^9/L to ≤200×10^9/L
Time frame:
Day 60
Reported as:
Count of participants · Participants
Proportion of Subjects Who Have a Platelet Count Between ≥50×10^9/L to ≤200×10^9/L
ParticipantsAvatrombopag
Proportion of Subjects Who Have a Platelet Count Between ≥50×10^9/L to ≤200×10^9/L36
SecondaryProportion of Subjects Who Have a Platelet Count Between ≥50×10^9/L to ≤200×10^9/L
Time frame:
Day 90
Reported as:
Count of participants · Participants
Proportion of Subjects Who Have a Platelet Count Between ≥50×10^9/L to ≤200×10^9/L
ParticipantsAvatrombopag
Proportion of Subjects Who Have a Platelet Count Between ≥50×10^9/L to ≤200×10^9/L33

Adverse events

Collected over 90 days. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Avatrombopag1/60 (1.7%)6/60 (10%)34/60 (56.7%)
Most frequent serious events
Most frequent serious events
EventAvatrombopag
ThrombocytopeniaBlood and lymphatic system disorders2/60
Rectal HaemorrhageGastrointestinal disorders1/60
Sudden DeathGeneral disorders1/60
OsteoarthritisMusculoskeletal and connective tissue disorders1/60
NephrolithiasisRenal and urinary disorders1/60
Most frequent other events
Showing 10 of 18
Most frequent other events
EventAvatrombopag
HeadacheNervous system disorders8/60
ContusionInjury, poisoning and procedural complications7/60
Oedema PeripheralGeneral disorders4/60
COVID-19Infections and infestations3/60
DizzinessEar and labyrinth disorders3/60
FatigueGeneral disorders3/60
Peripheral SwellingGeneral disorders3/60
ConstipationGastrointestinal disorders2/60
DiarrhoeaGastrointestinal disorders2/60
NauseaGastrointestinal disorders2/60

Baseline characteristics

Age, Continuous
Age, Continuous(years)Avatrombopag
Mean58.0 ± 21.7
Sex: Female, Male
Sex: Female, Male(Participants)Avatrombopag
Female37
Male23
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Avatrombopag
Hispanic or Latino13
Not Hispanic or Latino46
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Avatrombopag
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander1
Black or African American5
White43
More than one race1
Unknown or Not Reported8
08

Study locations

20 sites
  • Sobi Site 110
    Tucson, Arizona 85745, United States
  • Sobi Site 119
    Whittier, California 90603, United States
  • Sobi Site 123
    Washington, District of Columbia 20010, United States
  • Sobi Site 129
    Miami, Florida 33143, United States
  • Sobi Site 120
    Ocala, Florida 34474, United States
  • Sobi Site 125
    Saint Petersburg, Florida 33709, United States
  • Sobi Site 118
    Tampa, Florida 33606, United States
  • Sobi Site 126
    Chicago, Illinois 60612, United States
  • Sobi Site 109
    Peoria, Illinois 61614, United States
  • Sobi Site 124
    New Orleans, Louisiana 70112, United States
  • Sobi Site 101
    Bethesda, Maryland 20817, United States
  • Sobi Site 103
    Lincoln, Nebraska 68506, United States
  • Sobi Site 121
    Chapel Hill, North Carolina 27514, United States
  • Sobi Site 116
    Greenville, North Carolina 27834, United States
  • Sobi Site 128
    Cleveland, Ohio 44106, United States
  • Sobi Site 127
    Philadelphia, Pennsylvania 19104, United States
  • Sobi Site 102
    York, Pennsylvania 17403, United States
  • Sobi Site 104
    Rock Hill, South Carolina 29732, United States
  • Sobi Site 113
    Dallas, Texas 75246, United States
  • Sobi Site 108
    Salt Lake City, Utah 84132, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Jan 2024, 33 months.

Results were first posted in Jan 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2020
First posted
Nov 20, 2020
StartActual
Mar 15, 2021
Primary completionActual
Jan 3, 2024
CompletionActual
Jan 3, 2024
Results first posted
Jan 16, 2025
Last update
Jan 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04638829
Lead sponsor
Sobi, Inc.
Responsible party
Sponsor
First posted
Nov 20, 2020
Start date
Mar 15, 2021
Primary completion
Jan 3, 2024
Completion
Jan 3, 2024
Results posted
Jan 16, 2025
Last update
Jan 16, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avatrombopag

Start the discussion